| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From The Queen’s Cancer Institute (SAH), Honolulu, Hawaii; St. Vincent’s Comprehensive Cancer Center (JSM), New York, New York; Southwest Oncology Group Statistical Center (JB), Seattle, Washington; and The Tripler Army Medical Center (TF), Honolulu, Hawaii.
Correspondence: Address correspondence and reprint requests to: Scott A. Hundahl, MD, FACS, Medical Director, The Queen’s Cancer Institute, 1301 Punchbowl St., Honolulu, HI 96813; Fax: 808-537-7080; E-mail: shundahl{at}queens.org
Background: Intergroup 0116 (Southwest Oncology Group 9008), a national, multicenter, two-armed, prospective, randomized trial of adjuvant postoperative chemoradiotherapy, has demonstrated significant benefit.
Methods: We prospectively captured complete surgical information, including the treatment of various lymph node stations, for 553 of the 556 eligible participants in this trial. Before any survival analysis, we coded D level by using the Japanese general rules and used the Maruyama program to estimate the likelihood of disease in undissected regional node stations, defining the sum of these estimates as the Maruyama Index of Unresected Disease (MI). We analyzed survival with Cox multivariate regression.
Results: Fifty-four percent of participating patients underwent D0 lymphadenectomy. The median MI was 70 (range, 0–429). In contrast to D level, MI proved to be an independent prognostic factor, even with adjustment for the potentially linked variables of T stage and number of positive nodes. We detected no significant interaction between surgical or pathologic variables and the favorable effect of adjuvant treatment, but the power to detect such interaction was generally low.
Conclusions: MI, a measure of unresected regional nodal disease in gastric cancer, proved an independent predictor of survival. Surgical undertreatment, as observed in this trial, clearly undermined survival.
Key Words: Gastric cancer • Stomach cancer • Surgery • Lymphadenectomy • Quality • Survival
This article has been cited by other articles:
 |
|
 |
|
  M. Sasako, T. Sano, S. Yamamoto, Y. Kurokawa, A. Nashimoto, A. Kurita, M. Hiratsuka, T. Tsujinaka, T. Kinoshita, K. Arai, et al. D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer N. Engl. J. Med., July 31, 2008; 359(5): 453 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-C. Liao, J.-T. Lin, C.-Y. Wu, S.-P. Huang, M.-T. Lin, A. S.-H. Wu, Y.-J. Huang, and M.-S. Wu Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma Clin. Cancer Res., January 15, 2008; 14(2): 428 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sakuramoto, M. Sasako, T. Yamaguchi, T. Kinoshita, M. Fujii, A. Nashimoto, H. Furukawa, T. Nakajima, Y. Ohashi, H. Imamura, et al. Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine N. Engl. J. Med., November 1, 2007; 357(18): 1810 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Barbour, N. P. Rizk, M. Gonen, L. Tang, M. S. Bains, V. W. Rusch, D. G. Coit, and M. F. Brennan Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome Ann. Surg. Oncol., February 1, 2007; 14(2): 306 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Gee and D. W. Rattner Management of Gastroesophageal Tumors Oncologist, February 1, 2007; 12(2): 175 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ohtsu, S. Yoshida, and N. Saijo Disparities in Gastric Cancer Chemotherapy Between the East and West J. Clin. Oncol., May 10, 2006; 24(14): 2188 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nitti, J. Wils, J. G. Dos Santos, G. Fountzilas, P. F. Conte, C. Sava, A. Tres, R. C. Coombes, D. Crivellari, A. Marchet, et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG Ann. Onc., February 1, 2006; 17(2): 262 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Baxter and T. M. Tuttle Inadequacy of Lymph Node Staging in Gastric Cancer Patients: A Population-Based Study Ann. Surg. Oncol., December 1, 2005; 12(12): 981 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Smith, R. R. Schwarz, and R. E. Schwarz Impact of Total Lymph Node Count on Staging and Survival After Gastrectomy for Gastric Cancer: Data From a Large US-Population Database J. Clin. Oncol., October 1, 2005; 23(28): 7114 - 7124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Bouche, M. Ychou, P. Burtin, L. Bedenne, M. Ducreux, G. Lebreton, J. Baulieux, B. Nordlinger, C. Martin, J. F. Seitz, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801) Ann. Onc., September 1, 2005; 16(9): 1488 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P.M. Jansen, H. Boot, M. Verheij, and C. J.H. van de Velde Optimal Locoregional Treatment in Gastric Cancer J. Clin. Oncol., July 10, 2005; 23(20): 4509 - 4517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.A. Ajani, P.F. Mansfield, N. Janjan, J. Morris, P.W. Pisters, P.M. Lynch, B. Feig, R. Myerson, R. Nivers, D.S. Cohen, et al. Multi-Institutional Trial of Preoperative Chemoradiotherapy in Patients With Potentially Resectable Gastric Carcinoma J. Clin. Oncol., July 15, 2004; 22(14): 2774 - 2780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.H. Hartgrink, C.J.H. van de Velde, H. Putter, J.J. Bonenkamp, E. Klein Kranenbarg, I. Songun, K. Welvaart, J.H.J.M. van Krieken, S. Meijer, J.T.M. Plukker, et al. Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial J. Clin. Oncol., June 1, 2004; 22(11): 2069 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. P. Khatri and H. O. Douglass Jr D2.5 Dissection for Gastric Carcinoma Arch Surg, June 1, 2004; 139(6): 662 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.C.M.J. Peeters and C.J.H. van de Velde Improving Treatment Outcome for Gastric Cancer: The Role of Surgery and Adjuvant Therapy J. Clin. Oncol., December 1, 2003; 21(90230): 272s - 273. [Full Text] [PDF]
|
|
|
|
|
|
M. Sasako Principles of Surgical Treatment for Curable Gastric Cancer J. Clin. Oncol., December 1, 2003; 21(90230): 274s - 275. [Full Text] [PDF]
|
|
|
|
|
|
D. Nitti, A. Marchet, M. Olivieri, A. Ambrosi, R. Mencarelli, C. Belluco, and M. Lise Ratio Between Metastatic and Examined Lymph Nodes Is an Independent Prognostic Factor After D2 Resection for Gastric Cancer: Analysis of a Large European Monoinstitutional Experience Ann. Surg. Oncol., November 1, 2003; 10(9): 1077 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J.H. van de Velde and K. C.M.J. Peeters The Gastric Cancer Treatment Controversy J. Clin. Oncol., June 15, 2003; 21(12): 2234 - 2236. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
